Diagnostic Potential of CD44, CD133, and VDR in Epithelial Ovarian Tumors: Association with Histopathology Parameters
Authors:
- Ljubiša JovanovićLJLjubiša Jovanović
- Branka Šošić-JurjevićBŠBranka Šošić-Jurjević
- Anđa ĆirkovićAĆAnđa Ćirković
- Sandra DragičevićSDSandra Dragičević
- Branko FilipovićBFBranko Filipović
- Svetlana MilenkovićSMSvetlana Milenković
- Stefan DugalićSDStefan Dugalić
- Miroslava Gojnić-DugalićMGMiroslava Gojnić-Dugalić
- Aleksandra NikolićANAleksandra Nikolić
Open Access
- 15 April 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (8) , 3729
Abstract
Cancer stem cells (CSCs) significantly contribute to heterogeneity, malignancy, and therapy resistance in ovarian cancer. Recent studies emphasize the role of the vitamin D receptor (VDR) in regulating cell differentiation and stemness in various types of cancer. This study aims to determine the expression levels of CD44, CD133, and VDR in epithelial ovarian tumors (EOTs) and to compare these levels across different tumor types, including benign, atypical proliferative tumors, and five types of malignant phenotypes, in order to evaluate their potential as diagnostic tools for malignancy. Tissue samples from 218 patients diagnosed with EOT were analyzed. Clinical and histopathologic parameters were recorded. Quantitative immunohistochemical tissue microarray analysis was used to assess the expression levels of CD44, CD133, and VDR using two different scoring systems. Comparisons were made between benign tumors (n = 45), atypical proliferative tumors (n = 42), and ovarian carcinomas (n = 131), including high-grade serous (HGSC) and non-HGSC subtypes. Ovarian cancer, especially HGSC, showed a significantly higher expression of CD44 and VDR (p < 0.05) compared to atypical proliferative tumors and benign tumors. The expression of CD133 was highest in atypical proliferative tumors (p < 0.05). A moderate positive correlation was found between CD44, CD133, and VDR in all groups, with significant correlations with tumor grade and FIGO stage in ovarian cancer (p < 0.05). The increased expression of CD44 and VDR in aggressive ovarian cancer, along with elevated CD133 levels in atypical proliferative tumors, highlights the complexity of tumor biology. These markers may serve as valuable targets for the diagnosis of ovarian cancer.Keywords
Funding Information
- Ministry of Science, Technological Development and Innovations of the Republic of Serbia (451-03-136/2025-03/200007)
This publication has 51 references indexed in Scilit:
- Ovarian Cancer Stem Cells: Newer HorizonsThe Journal of Obstetrics and Gynecology of India, 2021
- Cytoplasmic VDR expression as an independent risk factor for ovarian cancerHistochemistry and Cell Biology, 2020
- CD133: beyond a cancer stem cell biomarkerJournal of Drug Targeting, 2018
- Expression of the stem cell marker CD133 is related to tumor development in colorectal carcinogenesisAsian Journal of Surgery, 2018
- Epidemiology of epithelial ovarian cancerBest Practice & Research Clinical Obstetrics & Gynaecology, 2017
- Immunohistochemical expression of stem cell markers CD44 and nestin in glioblastomas: Evaluation of their prognostic significancePathology - Research and Practice, 2016
- Ovary and fimbrial stem cells: biology, niche and cancer originsNature Reviews Molecular Cell Biology, 2015
- Tumor cell plasticity: the challenge to catch a moving targetJournal of Gastroenterology, 2014
- Cancer stem cellsThe International Journal of Biochemistry & Cell Biology, 2012
- Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological featuresVirchows Archiv, 2012